The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Open accessAbstract
Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–253 of 253
Antonowicz, S., Bodai, Z., Wiggins, T., Markar, S. R., Boshier, P. R., Goh, Y. M., Adam, M. E., Lu, H., Kudo, H., Rosini, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21800-5 · Cited by 50
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
Self-citationSuperoxide Anions Are Involved in Doxorubicin‐Induced ERK Activation in Hepatocyte Cultures
Navarro, R., Busnadiego, I., Ruiz‐Larrea, M. B., & Ruiz-Sanz, J. I. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.045 · Cited by 47
Strzeszewska, A., Alster, O., Mosieniak, G., Ciolko, A., & Sikora, E. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0069-5 · Cited by 47
Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma
Wang, J., Hu, C., Wang, J., Shen, Y., Bao, Q., He, F., Wang, H., Gong, L., Liu, Z., Hu, F., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000281 · Cited by 46
Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo
Besse, H. C., Rijbroek, A. D. B.-V., van der Wurff‐Jacobs, K. M. G., Bos, C., MOONEN, C. T. W., & Deckers, R. (2019) · Cancers · doi:10.3390/cancers11101512 · Cited by 46
Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells
Doroshow, J. H. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9474823 · Cited by 46
ATM at the crossroads of reactive oxygen species and autophagy
Xie, X., Zhang, Y., Wang, Z., Wang, S., Jiang, X.-Y., Cui, H., Zhou, T., He, Z., Feng, H., Guo, Q., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63963 · Cited by 46
Picardi, M., Giordano, C., Pugliese, N., Esposito, M. G., Fatigati, M., Muriano, F., Rascato, M. G., Pepa, R. D., d’Ambrosio, A., Vigliar, E., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18348 · Cited by 46
Yang, M., Liu, P., Wang, K., Glorieux, C., Hu, Y., Wen, S., Jiang, W., & Huang, P. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12032 · Cited by 45
Amani, J., Gorjizadeh, N., Younesi, S., Najafi, M., Ashrafi, A. M., Irian, S., Gorjizadeh, N., & Azizian, K. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103103 · Cited by 45
The relationship between DNA single-stranded damage response and double-stranded damage response
Ma, A., & Dai, X. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1403681 · Cited by 44
Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy
Qiu, C., Wu, Y., Shi, Q., Guo, Q., Zhang, J., Meng, Y., Wang, C., Xia, F., Wang, J., & Xu, C. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79328 · Cited by 44
Autophagy prevents doxorubicin-induced apoptosis in osteosarcoma
ZHAO, D., Yuan, H., YI, F., Meng, C., & Zhu, Q. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2055 · Cited by 43
Baranski, Z., Booij, T. H., Cleton-Jansen, A., Price, L., van de Water, B., Bovée, J. V. M. G., Hogendoorn, P. C. W., & Danen, E. H. J. (2015) · The Journal of Pathology · doi:10.1002/path.4528 · Cited by 42
Smith, J. A., Costales, A. B., Jaffari, M. V., Urbauer, D. L., Frumovitz, M., Kutac, C. K., Tran, H., & Coleman, R. L. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215594415 · Cited by 42
Kawase, M., Watanabe, M., Kondo, T., Yabu, T., Taguchi, Y., Umehara, H., Uchiyama, T., Mizuno, K., & Okazaki, T. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00301-3 · Cited by 41
Chang, Y. C., Fong, Y., Tsai, E., Chang, Y., Chou, H. L., Wu, C., Teng, Y., Liu, T., Yuan, S. F., & Chiu, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103010 · Cited by 40
Marques, L., Johnson, A. A., & Stolzing, A. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112203 · Cited by 39
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance.
Mohseni, M. M., Samadi, N., Ghanbari, P., Yousefi, B., Tabasinezhad, M., Sharifi, S., & Nazemiyeh, H. (2016) · PubMed Central · Cited by 38
Liu, X., Jiang, S., Wang, H., Wu, X., Yan, W., Chen, Y., Xu, Y., Wang, C., Yao, W., Wang, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1785 · Cited by 38
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Seetharamu, N., Preeshagul, I. R., & Sullivan, K. M. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s113177 · Cited by 37
Younes, M., Mardirossian, R., Rizk, L., Fazlian, T., Khairallah, J. P., Sleiman, C., Naim, H. Y., & Rizk, S. E. (2022) · Plants · doi:10.3390/plants11162137 · Cited by 36
IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma
Zhu, J., Li, Y., & Lv, X. (2022) · Immunogenetics · doi:10.1007/s00251-022-01275-4 · Cited by 35
Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB
Park, J. Y., Jang, M. J., Chung, Y. H., Kim, K. Y., Kim, S. S., Lee, W. B., You, S., Choi, Y. S., Hur, D. Y., & Kim, D. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.09.008 · Cited by 34
Wahba, J., Natoli, M., Whilding, L. M., Parente‐Pereira, A. C., Jung, Y., Zona, S., Lam, E. W. ‐., Smith, J. R., Maher, J. F., & Ghaem‐Maghami, S. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2199-8 · Cited by 34
Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells
Bedi, D., Henderson, H. J., Manne, U., & Samuel, T. (2019) · Medicines · doi:10.3390/medicines6020051 · Cited by 34
Joyner, D. E., Bastar, J. D., & Randall, R. L. (2006) · Journal of Orthopaedic Research® · doi:10.1002/jor.20169 · Cited by 32
5 Recent Studies on Doxorubicin and its Analogues
Brown, J., & Imam, S. H. (1985) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70410-7 · Cited by 32
Dessouki, F. B. A., Kukreja, R. C., & Singla, D. K. (2020) · Pharmaceuticals · doi:10.3390/ph13120450 · Cited by 31
Théard, D., Coisy‐Quivy, M., Ducommun, B., CONCANNON, P. J., & Darbon, J.-M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6095 · Cited by 30
Doxorubicin-Induced Thymus Senescence
Rukhsana Sultana, A., Domenico, F. D., Tseng, M. T., Cai, J., Noel, T. J., Chelvarajan, R. L., Pierce, W. M. J., Cini, C., Bondada, S., Clair, D. K. S., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr100465m · Cited by 29
Zhu, X., Xu, J. M., Cai, H., & Lang, J. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13521 · Cited by 29
di Rorà, A. G. L., Ghetti, M., Ledda, L., Ferrari, A., Bocconcelli, M., Padella, A., Napolitano, R., Fontana, M. C., Liverani, C., Imbrogno, E., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09640-x · Cited by 29
Chung, S. W., Kim, G. C., Kweon, S., Lee, H., Choi, J. U., Mahmud, F., Chang, H. W., Kim, J. W., Son, W., Kim, S. Y., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.007 · Cited by 27
Cancer-associated transcription factors in DNA damage response
Kciuk, M., Gielecińska, A., Kołat, D., Kałuzińska‐Kołat, Ż., & Kontek, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188757 · Cited by 27
Self-citationon behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO), Sehouli, J., Camara, O., Schmidt, M., Mahner, S., Seipelt, G., Otremba, B. J., Schmalfeldt, B., Tesch, H., Lorenz-Schlüter, C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0909-1 · Cited by 26
Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
Kciuk, M., Gielecińska, A., Mujwar, S., Mojzych, M., & Kontek, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073555 · Cited by 26
Self-citationCritical factors in the development of tumor-targeted anti-inflammatory nanomedicines
Coimbra, M., Crielaard, B. J., Storm, G., & Schiffelers, R. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.019 · Cited by 25
Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game
Arruda, F. D. S., Tomé, F. D., Miguel, M. P., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312110836 · Cited by 21
Strategies to release doxorubicin from doxorubicin delivery vehicles
Li, J., Zhang, B., Yue, C., Wu, J., Zhao, L., Sun, D., & Wang, R. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1363209 · Cited by 20
Doxorubicin‐induced senescence through NF‐κB affected by the age of mouse mesenchymal stem cells
Dezfouli, A. B., Amoli, J. S., Pourfathollah, A. A., Yazdi, M., Nikougoftar‐Zarif, M., Khosravi, M., & Hassan, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29140 · Cited by 20
Loh, J. S., Rahim, N. A., Tor, Y. S., & Foo, J. B. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3704 · Cited by 18
Sarkar, A. K., & Gandhi, V. V. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03917-1 · Cited by 16
Ji, P., Wang, X., Yin, J., Yao, Y., & Du, W. (2022) · Biomaterials Science · doi:10.1039/d2bm00079b · Cited by 15
Hlaváčová, M., Gumulec, J., Stračina, T., et al. (2015) · Physiological Research · doi:10.33549/physiolres.933223 · Cited by 14
Hu, C., Gu, F., Gong, C., Xia, Q., Gao, Y., & Gao, S. (2021) · Journal of Biomaterials Applications · doi:10.1177/08853282211060252 · Cited by 14
de Pádua, T. C., Marandino, L., Raggi, D., Johnson, J. E. H., Kutikov, A., Spiess, P. E., & Necchi, A. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.10.011 · Cited by 12
Moustafa, I., Viljoen, M., Perumal-Pillay, V. A., & Oosthuizen, F. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221147660 · Cited by 9
ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.
Cui, J., Dean, D. C., Hornicek, F. J., Pollock, R. E., Hoffman, R. M., & Duan, Z. (2022) · PubMed · Cited by 8
Mehrabian, A., Vakili‐Ghartavol, R., Mashreghi, M., Saremi, S. S., Badiee, A., Arabi, L., Alavizadeh, S. H., Moosavian, S. A., & Jaafari, M. R. (2021) · Research Square · doi:10.21203/rs.3.rs-742064/v1 · Cited by 7
Viale, M., Bertone, V., Maric, I., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105294 · Cited by 6
In vivo compatibility and degradation of crosslinked gelatin gels incorporated in knitted Dacron
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-4636(200007)51:1 · Cited by 4
Metadata
- Authors
- Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-02-19
- Volume
- 12
- Issue
- 4
- Pages
- 659
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4321372972
- Cited by
- 810
- References
- 253
- FWCI
- 513.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.